DTX-P7, a peptide–drug conjugate, is highly effective for non-small cell lung cancer

Yao Jiang1†, Wei Huang1†, Xiaojiao Sun2†, Xiaozhou Yang1†, Youming Wu1, Jiaojiao Shi1, Ji Zheng1, Shujie Fan1, Junya Liu1, Jun Wang1, Zhen Liang1, Nan Yang1*, Zhenming Liu1* and Yanyong Liu1*

Abstract
Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors including non-small cell lung cancer (NSCLC); however, non-selective adverse effects on healthy tissues and secondary resistance are the main obstacles. Meanwhile, the quiescent or dormant cancer stem-like cells (CSLCs) are resistant to antimitotic chemoradiotherapy. Complete remission can only be realized when both proliferative cancer cells and quiescent cancer stem cells are targeted. In the present research, we constructed a cooperatively combating conjugate (DTX-P7) composed of docetaxel (DTX) and a heptapeptide (P7), which specifically binds to cell surface Hsp90, and assessed the anti-tumor effects of DTX-P7 on non-small cell lung cancer. DTX-P7 preferentially suppressed tumor growth compared with DTX in vivo with a favorable distribution to tumor tissues and long circulation half-life. Furthermore, we revealed a distinctive mechanism whereby DTX-P7 induced unfolded protein response and eventually promoted apoptosis. More importantly, we found that DTX-P7 promoted cell cycle reentry of slow-proliferating CSLCs and subsequently killed them, exhibiting a "proliferate to kill" pattern. Collectively, by force of active targeting delivery of DTX via membrane-bound Hsp90, DTX-P7 induces unfolded protein response and subsequent apoptosis by degrading Hsp90, meanwhile awakens and kills the dormant cancer stem cells. Thus, DTX-P7 deserves further development as a promising anticancer therapeutic for treatment of various membrane-harboring Hsp90 cancer types.

Keywords: Non-small cell lung cancer, Heat shock protein 90 (Hsp90), Cancer stem-like cells (CSLCs), Cell cycle reentry, Dormancy, Targeting delivery, Unfolded protein response

†Yao Jiang, Wei Huang, Xiaojiao Sun and Xiaozhou Yang contributed equally to this work.
*Correspondence: yangnan@ibms.pumc.edu.cn; zmliu@bjmu.edu.cn; yanyongliu@ibms.pumc.edu.cn
1 Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
To the editor,
To address off-target toxicity of conventional chemotherapy, one effort is to enhance the targeted delivery by conjugating therapeutic effector through a cleavable linker to a ligand specific to a drug target, and several conjugates of targeting agents have been approved for application in oncology [1, 2]. However, simply enhancing drug delivery is of limited therapeutic benefit due to insufficiency to overcome the multitude of aberrant cellular processes. Strategies that simultaneously target multiple pathways will bring an opportunity to overcome the common obstacles such as drug resistance. Recently, we successfully identified a heptapeptide (LPLTPLP, namely P7) by phage display technique, which specifically binds to cell surface heat shock protein 90 (Hsp90) and reduces intracellular Hsp90 level in non-small cell lung cancer (NSCLC) cells [3]. It is well known that Hsp90 represents an attractive cancer therapeutic target with unique characteristics whereby its inhibition results in destabilization of multiple signaling pathways [4, 5]. More importantly, the Hsp90α isofrom, but not Hsp90β, is expressed on cell surface where it is involved in tumor invasiveness [6–10]. Therefore, it may be feasible to construct a peptide–drug conjugate to realize multifunctional effects including targeted delivery, cellular Hsp90 inhibition and combination with conventional drugs.
Herein, we designed and identified a peptide-conjugated drug comprising P7 and docetaxel (DTX) (namely DTX-P7) (Additional file 2: Fig. S1). We first evaluated the in-vivo efficacy of DTX-P7 in a mouse xenograft model of A549 cells. As shown in Fig. 1a, b, intraperitoneal administration of 20 mg/kg DTX-P7 (equivalent to DTX dose calculated as DTX) reduced tumor growth by 93.2% compared with control mice, whereas the tumor growth inhibition of DTX was only 35.9%. To investigate the targeting characteristics of DTX-P7, the biodistribution of both DTX and DTX-P7 was analyzed by high-performance liquid chromatography. DTX-P7 exhibited active targeting property by preferentially distributing to the tumor tissues (Fig. 1c and Additional file 3: Fig. S2).

Our previous study has shown that the heptapeptide P7 specifically binds to cell surface Hsp90 and inhibits expression of intracellular Hsp90 [3]. In this study, DTX-P7 inhibited the expression of membrane Hsp90 in dose- and time-dependent manners, while no change in mRNA level was observed, indicating posttranscriptional regulation of DTX-P7 (Fig. 1d, e). Cycloheximide chase assay and co-treatment of cells with bafilomycin A1 or bortezomib verified that DTX-P7 accelerates the degradation of Hsp90 through lysosome- and proteasome-dependent pathways (Fig. 1f–h). Furthermore, immunohistochemistry staining analysis of xenograft tumors also revealed decreased Hsp90 level in DTX-P7-treated mice, whereas treatment with DTX induced a significant increase in Hsp90 expression, reflecting an active adaption of tumor (Fig. 1i).

To identify the downstream molecular mechanism of DTX-P7-induced Hsp90 degradation, we performed a label-free quantitative proteomic analysis. The data demonstrated a widespread impact of DTX-P7 on proteins in cells and provided insight into the cellular pathways associated with phagosome, protein processing in endoplasmic reticulum (ER) and PI3K-Akt signaling pathway (Additional file 4: Fig. S3). We then confirmed the change of protein processing in endoplasmic reticulum by Western blotting analysis. As shown in Fig. 1j, k, DTX-P7 enhanced phosphorylation of PERK and eIF2α, whereas no XBP-1 RNA splicing was observed when A549 cells were exposed to DTX-P7, suggesting that DTX-P7 treatment induces the unfolded protein response (UPR) via PERK/eIF2α pathway. When the adaptive mechanism fails to restore normal ER function due to protracted or excessive stress stimuli, the UPR pathways may initiate apoptotic pathways to remove the stressed cells [11]. For
Fig. 1 (See legend on previous page.)
this reason, we observed cooperative combating effect of DTX-P7 to promote cell apoptosis (Fig. 1I–n). Based on the above findings, we conclude that DTX-P7 induces tumor cells to apoptosis and eventually death.

Cytotoxic agents that target killing rapidly proliferating cells are often difficult to produce good curative effects in the dormant or quiescent cancer stem cells in tumor tissues [12]. The presence of Hsp90 protein on the membrane of A549/CD133+ cancer stem cells was first confirmed, highlighting the potential application of P7 (Additional file 5: Fig. S4). Despite insignificant difference in vitro, DTX-P7 significantly reduced tumor growth in mice bearing xenograft of A549/CD133+ cells (Additional file 6: Fig. S5a and Fig. 2a, b). By staining with PKH26, a lipophilic dye which declines with every round of division and distinguishes rapidly and slowly proliferating cells by fluorescence intensity in cells, we found that both quiescent/slowly proliferating cells and fast proliferating cells were more sensitive to DTX-P7 than DTX (Fig. 2c and Additional file 6: Fig. S5b, c). In addition, DTX-P7 significantly reduced G0/G1 cells and arrested them in G2/M phase (Fig. 2d, e). DTX-P7 also reduced the expression of DYRK1A, which is known to regulate G1 phase where the cell cycle entry versus exit decision is made (Fig. 2f, g). A rise in cyclin D1 and a decline in p21 were observed as well. As a client protein of Hsp90, DYRK1A showed obvious ubiquitination following DTX-P7 treatment in A549/CD133+ cells (Fig. 2h). All these findings suggest that DTX-P7 suppresses survival of quiescent/slowly proliferating A549/CD133+ cells via degradation of DYRK1A and subsequent cell cycle reentry.

Collectively, a novel multifunctional DTX-P7 was successfully constructed for cancer therapy. In addition to active targeting delivery of DTX via Hsp90, DTX-P7 induces unfolded protein response and subsequent apoptosis, and awakens and kills the dormant cancer stem cells, making it a promising targeting strategy for lung cancer and other cancers where Hsp90 is highly expressed on cell surface.

(See figure on next page.)

**Fig. 2** DTX-P7 suppresses tumor growth of quiescent/slowly proliferating A549/CD133+ cells via degradation of DYRK1A and subsequent cell cycle reentry. 

- **a**: Volume of xenograft tumor mass. A549/CD133+ tumor-bearing mice were randomized into receive intraperitoneal injection of vehicle control, 15 mg/kg DTX-P7, 30 mg/kg DTX-P7 or 15 mg/kg DTX once a week for 4 weeks (n = 7 mice/group). Data are represented by mean ± SEM. Arrows indicate the treatments.
- **b**: Tumor tissues were dissected and weighed when the animals were euthanized in 4 weeks post treatment. 
- **c**: A549/CD133+ mock-sorted (untreated) or sorted into PKH26high and PKH26low populations were incubated for 72 h with 10 μM DTX or 10 μM DTX-P7 followed by cell viability assay.
- **d–e**: A549/CD133+ cells were treated with vehicle control, DTX-P7, DTX or 17-AAG for 48 h followed by cell cycle analyses by propidium iodide. 
- **f**: A549/CD133+ cells were treated with 0, 15, 30 nM DTX-P7 or 15 nM DTX for 48 h followed by total cell lysate preparation and Western blotting analysis. 
- **g**: Total lysate preparation and Western blotting analysis of tumor tissues.

β-actin was used as a loading control. 

A549/CD133+ cells were transfected with HA-Ubiquitin followed by treatment with vehicle control or 30 nM DTX-P7 for 24 h. The lysates were immunoprecipitated using an anti-DYRK1A antibody, followed by immunoblotting with an anti-HA antibody under denaturing conditions. *p < 0.05, **p < 0.01, versus control group.
Fig. 2 (See legend on previous page.)
Abbreviations
CSSL: Cancer stem-like cell; DTX: Docetaxel; DYRK1A: Dual-specificity tyrosine-(Y)-phosphorylation-regulated protein kinase 1A; eIF2α: Eukaryotic translation initiation factor 2α; ER: Endoplasmic reticulum; Hsp90: Heat shock protein 90; NSCLC: Non-small cell lung cancer; PERK: Protein kinase R-like endoplasmic reticulum kinase; PI3K: Phosphatidylinositol 3-kinase; UPR: Unfolded protein response; XBP-1: X-box-binding protein-1.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045-022-01274-8.

Additional file 1: Methods.
Additional file 2: Supplementary Figure S1. Characterization of DTX-P7 conjugate. a) Chemical structures of DTX and DTX-P7. DTX, molecular formula C39H47N6O14, molecular weight 722.1 g/mol, white powder. DTX-P7, molecular formula C66H100N14O28, molecular weight 1299.2 g/mol, white powder. b) Cell viability of DTX-P7 and DTX in A549 (b) and H1975 (c) cells following 48-h treatment. IC50 values: A549 cells, DTX-P7 11.4 nM, DTX 11.1 nM; H1975 cells, DTX-P7 0.62 nM, DTX 0.50 nM.

Additional file 3: Supplementary Figure S2. Biodistribution of DTX-P7 in nude mice bearing A549 xenograft tumor. DTX-P7 was quantified by free DTX released from the conjugate. a) Plasma concentration of DTX and DTX-P7 in plasma samples throughout 72-h treatment. b-e) Distribution of DTX in the heart, liver, spleen, lungs, kidneys, and brain in 1 h (b), 2 h (c), 4 h (d) and 8 h (e) after DTX or DTX-P7 was administered to mice implanted with A549 xenograft tumor. Data are given as mean ± SD (n = 3). * p < 0.05 vs. DTX group.

Additional file 4: Supplementary Figure S3. Proteome changes induced in A549 cells by DTX-P7. a-c) Gene Ontology (GO) annotation analysis of A549 cell proteins that changed more than 1.5-ratio after DTX-P7 treatment, including altered proteins for biological process (a), cellular component (b) and molecular function (c) analyses. d) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation analysis of A549 cell proteins that changed more than 1.5-ratio after DTX-P7 treatment.

Additional file 5: Supplementary Figure S4. Cell growth morphology of cancer stem cell-like A549/CDS333 cells and identification of cell surface Hsp90 in A549/CDS333 cells. a) Morphology of A549 and A549/CDS333 cells. b) Hsp90 expression levels were assessed in A549/CDS333 cells by cellular fractionation and Western blotting analysis. c) Immunofluorescence analysis of cell surface Hsp90 in A549/CDS333 cells. d) Immunofluorescence assays of FITC-labeled P7 binding to A549/CDS333 cells. Competition of P7 binding to A549/CDS333 cells by excess free P7.

Additional file 6: Supplementary Figure S5. Effects of DTX-P7 on survival of A549/CDS333 cells and PKH26 staining of A549/CDS333 cells. a) Cell viability of DTX-P7 and DTX in A549/CDS333 cells following 48-h treatment. b) A549/CDS333 cells were stained by PKH26 followed by fluorescence detection at Day 0, 1, 6 and 10. c) Representative fluorescence-activated cell sorting profile of A549/CDS333 cells selected for sorting 10 days after PKH26 staining as compared with those of the unstained control (negative control) and Day 0.

Acknowledgements
We thank Dr. Deng Chen in PUMC for the generous gift of HA-Ub expression plasmid.

Author contributions
YJ, WH and YYL made substantial contributions to conception and design of the study. YJ, WH, XJS, XZY, YMW, JJS, JZ, SJF, JYL, JW and LZ performed the experiments and analyzed the data in this study. WH was a major contributor in writing the manuscript. YJ, NY and ZML reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the grants from National Science and Technology Major Projects for Major New Drugs Innovation and Development (2019ZX09301170), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-12M-0-026), Natural Science Foundation of Beijing Municipality (7172134 and 7192128), National Natural Science Foundation of China (81972688) and PUMC Youth Fund and Fundamental Research Funds for the Central Universities (3332011133 and 2017550002).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplemental material file.

Declarations
Ethics approval and consent to participate
All the animal experiments were approved by the Institutional Animal Care and Use Committee of the Chinese Academy of Medical Science and were conducted in accordance with the recommendations of “Regulations of experimental animals.”

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, China. 2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

Received: 18 April 2022  Accepted: 23 April 2022

Published online: 03 June 2022

References
1. Gauzy-Lazo L, Sassoon I, Brun MP. Advances in antibody–drug conjugate design: current clinical landscape and future innovations. SLAS Discov. 2020;25(8):843–68. https://doi.org/10.1177/247255520912955.
2. Chen H, Lin ZT, Arntz KE, Miller DO, Liu W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):1281. https://doi.org/10.3390/molecules22081281.
3. Jiang Y, Yang N, Zhang HF, Sun B, Hou CY, Ji C, et al. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. J Control Release. 2016;221:26–36. https://doi.org/10.1016/j.jconrel.2015.11.029.
4. Birbo B, Mudu EE, Mudu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2022;22(19):10317. https://doi.org/10.3390/ijms221910317.
5. Liu Y, Xiao L. Recent advances in the development of novel HSP90 inhibitors: an update from 2014. Curr Drug Targets. 2020;21(3):302–17. https://doi.org/10.2174/1389450120666190829162544.
6. Chen WS, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90α (HSP90α) induces nuclear factor-κB-mediated TCF12F protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion. J Biol Chem. 2013;288(13):9001–10. https://doi.org/10.1074/jbc.M112.437897.
7. Li W, Sahu D, Tsen F. Secreted heat shock protein 90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta. 2012;1823(3):370–41. https://doi.org/10.1016/j.bbaexp.2011.09.029.
8. Tang X, Chang C, Guo J, Lincoln V, Liang C, Chen M, et al. Tumour-secreted Hsp90α on external surface of exosomes mediates tumour - stromal cell communication via autocrine and paracrine mechanisms. Sci Rep. 2019;9(1):15108. https://doi.org/10.1038/s41598-019-51704-w.
9. Poggio P, Sorge M, Secci L, Brancaccio M. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metasta- sis. Front Cell Dev Biol. 2021;9:735529. https://doi.org/10.3389/fcell.2021.735529.
10. Wong DS, Jay DG. Emerging roles of extracellular Hsp90 in cancer. Adv Cancer Res. 2016;129:141–63. https://doi.org/10.1016/bs.acr.2016.01.001.
11. Corazzari M, Gagliardi M, Fimia GM, Piacentini M. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol. 2017;7:78. https://doi.org/10.3389/fonc.2017.00078.

12. Takeishi S, Nakayama KI. To wake up cancer stem cells, or to let them sleep, that is the question. Cancer Sci. 2016;107(7):875–81. https://doi.org/10.1111/cas.12958.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.